Cargando…

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

We investigated PD-L1 changes in response to MEK and AKT inhibitors in KRAS mutant lung adenocarcinoma (adeno-NSCLC). PD-L1 expression was quantified using immunofluorescence and co-culture with a jurkat cell-line transfected with NFAT-luciferase was used to study if changes in PD-L1 expression in c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minchom, Anna, Thavasu, Parames, Ahmad, Zai, Stewart, Adam, Georgiou, Alexandros, O’Brien, Mary E. R., Popat, Sanjay, Bhosle, Jaishree, Yap, Timothy A., de Bono, Johann, Banerji, Udai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628934/ https://www.ncbi.nlm.nih.gov/pubmed/28982179 http://dx.doi.org/10.1371/journal.pone.0186106

Ejemplares similares

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
por: Broutin, Sophie, et al.
Publicado: (2016)

HER3 expression and MEK activation in non-small-cell lung carcinoma
por: Manickavasagar, Thubeena, et al.
Publicado: (2021)

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach
por: Pender, Alexandra, et al.
Publicado: (2015)

Searching for treatments for non-G12C-KRAS mutant cancers
por: Guo, Christina, et al.
Publicado: (2021)

Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
por: Collins, Dearbhaile Catherine, et al.
Publicado: (2020)

Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
por: Collins, Dearbhaile Catherine, et al.
Publicado: (2021)

A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma
por: Minchom, Anna, et al.
Publicado: (2019)

Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond
por: Joshi, Kroopa, et al.
Publicado: (2021)

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
por: Coker, Elizabeth A., et al.
Publicado: (2022)

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic
por: Tiu, Crescens, et al.
Publicado: (2020)

Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience
por: Cui, Wanyuan, et al.
Publicado: (2020)

A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF(V600) wild-type colorectal cancer
por: Georgiou, Alexandros, et al.
Publicado: (2021)

Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models
por: Wong Te Fong, Anne-Christine, et al.
Publicado: (2017)

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
por: Stewart, A., et al.
Publicado: (2015)

Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice
por: Abdelraouf, Fatma, et al.
Publicado: (2015)

1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience
por: Cui, W., et al.
Publicado: (2020)

Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)
por: Pal, Abhijit, et al.
Publicado: (2021)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
por: O’Brien, Mary E. R., et al.
Publicado: (2018)

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19
por: Cui, W., et al.
Publicado: (2021)

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
por: Minchom, Anna, et al.
Publicado: (2020)

Epidermal Growth Factor Mutation as a Diagnostic and Therapeutic Target in Metastatic Poorly Differentiated Thyroid Carcinoma: A Case Report and Review of the Literature
por: Lote, Hazel, et al.
Publicado: (2014)

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications
por: Hindocha, Sumeet, et al.
Publicado: (2021)

Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy
por: Castagnoli, Francesca, et al.
Publicado: (2022)

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B(12) and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity
por: Minchom, A R, et al.
Publicado: (2014)

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
por: Linch, Mark, et al.
Publicado: (2014)

1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond
por: Joshi, K., et al.
Publicado: (2020)

Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells
por: Hara, Toshifumi, et al.
Publicado: (2014)

A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy
por: Tiu, Crescens, et al.
Publicado: (2021)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy
por: Dai, Xin, et al.
Publicado: (2015)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
por: Begum, Parvin, et al.
Publicado: (2021)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Genome-wide DNA methylation analysis of KRAS mutant cell lines
por: Tew, Ben Yi, et al.
Publicado: (2020)

Targeting the DNA replication stress phenotype of KRAS mutant cancer cells
por: Al Zubaidi, Tara, et al.
Publicado: (2021)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre
por: O’Carrigan, Brent, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k8efjo75bj1e1hlu89hg6gm8nb